Mr. Mike Piccinino reports

HELIUS MEDICAL TECHNOLOGIES, INC. ANNOUNCES PRICING OF PUBLIC OFFERING OF CLASS A COMMON STOCK

Helius Medical Technologies Inc. has priced an underwritten public offering of 2,121,212 shares of its Class A common stock at a public offering price of $8.25 per share, before underwriting discounts and commissions. The net proceeds to Helius from this offering, after deducting the underwriting discounts, commissions and estimated offering expenses payable by Helius, are expected to be approximately $15.7-million. The offering is expected to close on or about Monday, Nov. 19, 2018, subject to customary closing conditions including the approval of the Toronto Stock Exchange.

BTIG LLC and Oppenheimer & Co. Inc. are acting as joint book-running managers for the offering. Haywood Securities Inc. is acting as a co-manager for the offering. Helius has granted the underwriters a 30-day option to purchase up to an additional 318,182 shares of Class A common stock at the public offering price, less the underwriting discounts and commissions.

The offering is being made by means of written prospectuses and prospectus supplements that form part of Helius's existing Canadian MJDS short-form base shelf prospectus dated Jan. 26, 2017, in Canada, and effective United States shelf registration statement on Form S-3 dated Jan. 6, 2017, in the United States. Preliminary prospectus supplements and the accompanying prospectuses have been filed with the securities regulatory authorities in all provinces of Canada, pursuant to the multijurisdictional disclosure system, and with the Securities and Exchange Commission (SEC) in the United States. Copies of these documents, as well as the final prospectus supplements and the accompanying prospectuses, will be available on the company's profiles on the SEDAR website maintained by the Canadian Securities Administrators or the SEC's website, as applicable. Alternatively, when available, copies of the final prospectus supplements and the accompanying prospectuses may also be obtained for free from BTIG at 825 Third Ave., sixth floor, New York, N.Y., 10022, by telephone at 212-593-7555, or by e-mail to equitycapitalmarkets@btig.com or from Oppenheimer, attention: Syndicate Prospectus Department, 85 Broad St., 26th floor, New York, N.Y., 10004, by telephone at 212-667-8055 or by e-mail at EquityProspectus@opco.com.

About Helius Medical Technologies Inc.

Helius Medical Technologies is a neurotech company focused on neurological wellness. The company's purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain's ability to heal itself. The company's first product in development is the portable neuromodulation stimulator.